Private insurers in the U.S. have mostly declined to cover Aduhelm, saying they need more proof of its efficacy and that benefits outweigh risks like brain swelling.
By Deena Beasley (Reuters) - The future of Aduhelm, Biogen Inc's controversial and expensive Alzheimer's drug, may hinge on a decision due this week f.
The future of Aduhelm, Biogen Inc s controversial and expensive Alzheimer s drug, may hinge on a decision due this week from the U.S. Medicare program on whether it will pay for the treatment.. | January 11, 2022
Future of Biogen s Aduhelm hinges on U S Medicare Alzheimer s coverage streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.